|
|
|
|
 |
|
SENSEX
|
 |
-364.20
|
-1.52%
|
|
23587.50
|
|
|
|
NIFTY
|
|
-1176.46
|
-1.49%
|
|
78041.59
|
|
|
|
Nasdaq
|
 |
199.83
|
1.03%
|
|
19572.60
|
|
|
|
Nikkei 225
|
|
-111.68
|
-0.29%
|
|
38701.90
|
|
|
|
FTSE 100
|
|
-20.70
|
-0.26%
|
|
8084.60
|
|
|
 |
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15-05-2024
|
|
|
|
| Mankind Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. |
|
|
|
|
|
15-05-2024
|
|
|
|
| Mankind Pharma Limited has informed the Exchange regarding Change in Auditors of the company. |
|
|
|
|
|
15-05-2024
|
|
|
|
| MANKIND PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
|
|
|
|
|
15-05-2024
|
|
|
|
| Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024. |
|
|
|
|
|
15-05-2024
|
|
|
|
| Mankind Pharma Limited has informed the Exchange about Investor Presentation |
|
|
|
|
|
15-05-2024
|
|
|
|
| The Exchange has sought clarification from Mankind Pharma Limited with respect to recent news item captioned Mankind Pharma in fray to acquire Advent's stake in Bharat Serums. The response from the Company is awaited. |
|
|
|
|
|
15-05-2024
|
|
|
|
| Outcome of Board meeting held today i.e. May 15, 2024. |
|
|
|
|
|
15-05-2024
|
|
|
|
| Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results for the quarter and financial year ended on March 31, 2024. |
|
|
|
|
|
15-05-2024
|
|
|
|
| The Board of Directors of the Company at its meeting held today i.e. May 15, 2024, has inter-alia, considered and approved the:3. Raising of funds by way of issuance of such number of equity shares having face value of ₹ 1 each of the Company ( Equity Shares ) and / or other eligible securities or any combination thereof (hereinafter referred to as Securities ), for an aggregate amount not exceeding ₹ 7,500 crores (Rupees Seven Thousand Five Hundred Crores only) or an equivalent amount thereof by way of issuance of equity / equity linked securities under qualified institutional placement ( QIP ) or through issuance of FCCBs, ADRs / GDRs / debt securities or through any other permissible mode in accordance with the applicable laws, subject to the receipt of the necessary approvals including the approval of the members of the Company and other regulatory / statutory approvals, as may be required. |
|
|
|
|
|
10-05-2024
|
|
|
|
| Allotment of 46,698 Equity Shares under Mankind Pharma Limited Employee Stock Option Plan 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|